Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer.

Terzuoli E, Donnini S, Finetti F, Nesi G, Villari D, Hanaka H, Radmark O, Giachetti A, Ziche M.

Oncotarget. 2016 Jul 12;7(28):44350-44364. doi: 10.18632/oncotarget.10051.

2.

Is there still a place for docetaxel rechallenge in prostate cancer?

Petrioli R, Francini E, Roviello G.

World J Clin Oncol. 2015 Oct 10;6(5):99-103. doi: 10.5306/wjco.v6.i5.99.

3.

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.

Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H.

J Steroid Biochem Mol Biol. 2013 Nov;138:248-56. doi: 10.1016/j.jsbmb.2013.06.002. Epub 2013 Jun 20. Review.

4.

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E.

Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi: 10.4161/cbt.21188. Epub 2012 Jul 24. Review.

5.

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.

Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, Smith D, Baranowski K, Vaishampayan U.

ISRN Oncol. 2012;2012:242850. doi: 10.5402/2012/242850. Epub 2012 Jun 13.

6.

Emerging targeted therapies for castration-resistant prostate cancer.

Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N.

Front Endocrinol (Lausanne). 2012 May 31;3:73. doi: 10.3389/fendo.2012.00073. eCollection 2012.

7.

Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.

Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q.

PLoS One. 2012;7(4):e35629. doi: 10.1371/journal.pone.0035629. Epub 2012 Apr 23.

8.

Castration-resistant prostate cancer: mechanisms, targets, and treatment.

Amaral TM, Macedo D, Fernandes I, Costa L.

Prostate Cancer. 2012;2012:327253. doi: 10.1155/2012/327253. Epub 2012 Mar 5.

9.

Targeting angiogenesis for the treatment of prostate cancer.

Antonarakis ES, Carducci MA.

Expert Opin Ther Targets. 2012 Apr;16(4):365-76. doi: 10.1517/14728222.2012.668887. Epub 2012 Mar 13. Review.

10.

Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.

Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R.

Prostate Cancer. 2011;2011:258689. doi: 10.1155/2011/258689. Epub 2011 Aug 21.

11.

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

Bousquet G, Alexandre J, Le Tourneau C, Goldwasser F, Faivre S, de Mont-Serrat H, Kaiser R, Misset JL, Raymond E.

Br J Cancer. 2011 Nov 22;105(11):1640-5. doi: 10.1038/bjc.2011.440. Epub 2011 Oct 25.

12.

MET and VEGF: synergistic targets in castration-resistant prostate cancer.

Aftab DT, McDonald DM.

Clin Transl Oncol. 2011 Oct;13(10):703-9. doi: 10.1007/s12094-011-0719-5. Review.

13.

Current treatment strategies for castration-resistant prostate cancer.

Kim SJ, Kim SI.

Korean J Urol. 2011 Mar;52(3):157-65. doi: 10.4111/kju.2011.52.3.157. Epub 2011 Mar 18.

14.

Recent developments in prostate cancer biomarker research: therapeutic implications.

Detchokul S, Frauman AG.

Br J Clin Pharmacol. 2011 Feb;71(2):157-74. doi: 10.1111/j.1365-2125.2010.03766.x. Review.

15.

Future directions in castrate-resistant prostate cancer therapy.

Antonarakis ES, Carducci MA.

Clin Genitourin Cancer. 2010 Dec 1;8(1):37-46. doi: 10.3816/CGC.2010.n.006. Review.

16.

Angiogenesis inhibitors in the treatment of prostate cancer.

Hwang C, Heath EI.

J Hematol Oncol. 2010 Aug 2;3:26. doi: 10.1186/1756-8722-3-26. Review.

17.
18.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.

J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.

19.

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM.

Oncologist. 2010;15(2):130-41. doi: 10.1634/theoncologist.2009-0252. Epub 2010 Feb 5. Review.

20.

Angiogenesis inhibitors in the treatment of prostate cancer.

Kluetz PG, Figg WD, Dahut WL.

Expert Opin Pharmacother. 2010 Feb;11(2):233-47. doi: 10.1517/14656560903451716. Review.

Supplemental Content

Support Center